Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
10
Iron-Sirr Coregulation of S.Epidermidis Virulence
Award last edited on: 1/11/07
Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$123,294
Award Phase
1
Solicitation Topic Code
-----
Principal Investigator
Robert J Harrison
Company Information
Advanced Microbial Solutions Corporation
321 Fortune Boulevard
Milford, MA 01757
(617) 868-6364
anjin_group@earthlink.net
N/A
Location:
Single
Congr. District:
04
County:
Worcester
Phase I
Contract Number:
1R43AI049617-01
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2001
Phase I Amount
$123,294
Iron is an important co-regulator of virulence in many bacterial species including Staphylococcus aurues and Staphylococcus epidermidis both significant human pathogens. The iron dependent transcriptional regulator DtxR [diphtheria toxin repressor] originally identified in Corynebacterium diphtheriae plays a critical role in virulence. DtxR functions as an iron sensor selectively silencing gene expression when iron is readily available. When iron levels become limiting the repressor dissociates and iron dependent genes are de-repressed. DtxR homologues can be identified in a number of gram positive pathogens including SirR in Staphylococcus epidermidis. While it is unlikely that all virulence determinants within a genera or specific species of bacteria are tied to one of these regulators it is reasonable to propose that a significant proportion rely on iron co-regulation of virulence. In Staphylococcus epidermidis both the uptake of iron from the environment and the production of bioflim appear to be at least partially regulated by the availability of iron. This proposal seeks to determine the feasibility of targeting the DtxR homologue SirR from Staphylococcus epidermidis as a potential drug target. PROPOSED COMMERCIAL APPLICATION: Direct application of existing primary to isolate iron independent SirR and test for alterations in virulence in S. epidermidis. Development of drug target to treat infections associated with medical devices. Percentage of annual $US6 billion antimicrobial drug market
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.